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Chronic hepatitis C virus infection is currently the most common cause of end
stage liver disease worldwide. Although the conclusions of the last National
Institutes of Health Consensus Development Conferences on Hepatitis C have
recently been published, several important issues remain unanswered. this
paper reviews the available data using an evidence-based approach. Current
evidence is sufficient to recommend IFN treatment for all patients with acute
hepatitis. A later initiation of therapy yields the same likelihood of response
as early treatment. A daily induction dose during month 1 is the best treat-
ment option. The current gold standard of efficacy for treatment-naive
patients with chronic hepatitis C is the combination of pegylated IFN and rib-
avirin. The overall sustained viral response rate to these regimens is 54 – 56%
following a 48-week course of therapy. Patients with genotype 1 infection
will have a 42 – 51% likelihood of response to 48 weeks of therapy. Those
with genotypes 2 or 3 infection will respond to 24 weeks in 78 – 82% of cases.
Debate continues regarding the optimal dose and duration of peginterferon
(PEG-IFN), not only in patients infected with genotype 2 or 3 but also in those
infected with genotype 1. The optimal dose of ribavirin has yet to be deter-
mined. Available data show the need to give the highest tolerable doses
(1000 – 1200 mg/day) to the difficult-to-treat patients (genotype 1, cirrhotics,
obese), although there is a greater likelihood of intolerance. Genotypes 2
and 3 may receive 800 mg/day, which is also the most appropriate lower dose
for those patients who require dosage modification for anaemia or other
side effects. Tolerability and compliance to therapy are still a problem, as
~ 15 – 20% of patients within trials and > 25% in clinical practice withdraw
from therapy. New PEG-IFNs are more effective than conventional IFN in
improving liver histology. Monotherapy with PEG-IFN induces a marked
reduction in staging in virological sustained responders, and to a lesser
degree in relapsers, but provides no benefit to nonresponders after 24 –
48 weeks of treatment. The use of maintenance therapy in virological nonre-
sponders aiming to improve histology should be considered experimental
and of unproven benefit. Pooling data from the literature suggests a slight
preventive effect of IFN on hepatocellular carcinoma development in
patients with HCV-related cirrhosis. The magnitude of this effect is low and
the observed benefit may be due to spurious associations. The preventive
effect is more evident among sustained responders to IFN.
Keywords: combination treatment, hepatitis C, histological benefit, meta-analysis, 
pegylated interferon
Expert Opin. Pharmacother. (2005) 6(3):xxx-xxx
1.  Background
Hepatitis C virus (HCV) infection is a major health problem worldwide. Chronic
hepatitis C is a relevant cause of morbidity and mortality, which could create a sig-
nificant future public health burden [1-3]. However, only an estimated 20 – 40% of
1. Background
2. When and how to treat acute 
hepatitis C?
3.  What is the optimal schedule 
for treatment-naive chronic 
hepatitis C patients?
4.  What is the histological benefit 
of antiviral therapy?
5. What is the overall effect of IFN 
treatment on the prevention of 
hepatocellular carcinoma in 
hepatitis C virus-related 
cirrhosis?
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subjects chronically infected by HCV will eventually develop
cirrhosis within 15 – 30 years and die from related complica-
tions [4]. These subjects would be the ideal candidates for
treatment, but they are not easy to identify in the presympto-
matic phase of the disease. Therefore, a universal cure for
patients with chronic hepatitis C remains an elusive goal.
Almost 15 years after the first randomised controlled trial
(RCT) of IFN therapy in chronic hepatitis C [5], the optimal
strategy of treatment of HCV infection remains a matter of
debate. Firstly, a substantial proportion (approximately two-
thirds) of HCV-infected patients may not be candidates for
currently available antiviral treatment for several reasons [6].
Secondly, despite the availability of new and highly effective
antiviral treatment, the number of patients who still do not
respond to currently available therapies is significant and the
new combination regimens of peginterferon (PEG-IFN) and
ribavirin are still poorly tolerated [7]. Finally, a major concern is
the fact that RCTs of antiviral therapy for chronic hepatitis C
have mostly been performed in highly selected population and
in patients without advanced fibrosis or cirrhosis. Hence, the
transferability of these results to the whole spectrum of sub-
jects with chronic liver disease due to HCV is questionable.
Although the conclusions of the last National Institutes of
Health Consensus Development Conferences on Hepatitis C
have recently been published [8], several important questions
in the management of HCV-infected patients still remain
unanswered:
• When and how to treat acute hepatitis C?
• What is the optimal schedule of treatment for chronic hep-
atitis C?
• What is the histological benefit of antiviral therapy in
chronic hepatitis C?
• Is the risk of hepatocellular carcinoma (HCC) truly
reduced by antiviral therapy?
In order to answer these relevant issues, this paper will review
the available data using an evidence-based approach.
2.  When and how to treat acute hepatitis C?
In 2002, the final statement from the National Institutes of
Health (NIH) Consensus Conference on the Management of
Hepatitis C was that treatment of patients with acute hepatitis
C is warranted, and that the minimum dose required for
patients with acute hepatitis C to obtain a significant benefit
is IFN-α 3 MU three times weekly for at least 12 weeks [9].
However, two unresolved issues remain: when therapy should
be started and the optimal schedule of treatment. In order to
solve the two issues, the benefit of IFN on acute hepatitis C
was evaluated by a recently published meta-analysis [10] that
included analysis of 12 controlled trials (445 patients). A large
variability in IFN schedule was found with regard to both the
total dose which ranged between 3 and 5 – 6 MU, and the
length of treatment (range: 4 – 24 weeks). Patients began
treatment at different time points from the onset of the dis-
ease, ranging from 15 to 90 days. The mean length of post-
treatment follow-up was 16 months (range: 6 – 36 months).
IFN significantly increased viral clearance in all but two tri-
als by Calleri et al. and by Fabris et al. (Figure 1). The pooled
estimate of the sustained virological response (SVR) was sta-
tistically significant and clinically relevant (risk difference
[RD] +49%; 95% CI = 33 – 65%; p < 0.00001; number
needed to treat [NNT] = 2). The magnitude of treatment
effect was different among studies: the RD of each trial
ranged from +5 to +90%. It is possible that this reflects differ-
ences in the treatment schedules and in other clinical charac-
teristics of the patients enrolled in the studies. The RD of
sustained virological response increased when trials were
ordered by increasing total weekly dose, suggesting that
induction with a high weekly dose of IFN (≥ 21 MU/week) is
the most effective option. Delaying therapy by 60 days after
onset of symptoms did not reduce the efficacy of treatment.
Overall safety in all trials was good and jaundiced or sympto-
matic affected patients did not shown any severe side effects.
The results of this meta-analysis are subject to several limi-
tations. The available studies are of small size and heterogene-
ous in methodological quality and design (many of the
included studies were nonrandomised controlled trials). The
small sample size is justified because it is difficult to enroll
patients at diagnosis, either due to the lack of specific diagnos-
tic tests or because the disease is often asymptomatic and
rarely recognised outside of surveillance programmes. The
studies did not clearly define how the enrolled patients were
selected. No study reported whether or not the patients were
consecutively enrolled or how many potentially eligible sub-
jects did not enter the trials.
Currently available evidence supports standard IFN mono-
therapy as treatment for acute hepatitis C. A daily induction
dose of at least 21 MU/week during month 1 is the best
option, and delaying therapy by 8 – 12 weeks after the onset
of disease does not compromise the response to treatment.
Assessment of the efficacy safety and costs of PEG-IFN or
PEG-IFN and ribavirin combination therapy in acute hepati-
tis C has not been evaluated so far.
3.   What is the optimal schedule for treatment-
naive chronic hepatitis C patients?
The current gold standard of efficacy for treatment is the
combination of PEG-IFN and ribavirin [11]. The overall SVR
rates following the use of these regimens is 54 – 56% after a
48-week course of therapy. Patients with genotype 1 infection
will have a 40 – 50% likelihood of response to 48 weeks of
therapy [12-19]. Those with genotypes 2 or 3 infection will
respond to 24 weeks in 75 – 80% of cases [12-19]. These rates
are 5 – 10% higher in all patient groups than those obtained
with standard IFN-α and ribavirin. Other conventional pre-
dictors of low responsiveness, such as high viral load or
advanced liver fibrosis, affect the response to pegylated inter-
ferons less than they do with standard IFN [12-19].
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However, these results may not represent the experience of
the entire HCV-infected population because most studies
have used highly selected patient groups, have been per-
formed in referral centres, and have not reported the screening
sample size. Therefore, the extent to which the results of clini-
cal trials in HCV-infected patients apply to the entire HCV-
infected population is unknown. Finally, a major issue of con-
cern is the fact that adherence and compliance with therapy, a
paramount factor in obtaining high rates of SVR in patients
receiving PEG-IFN and ribavirin [7], are still low, and accurate
and reliable clinical predictors of compliance are still lacking.
Important questions remain unanswered. What is the opti-
mal treatment regimen for naive patients? Are there any dif-
ferences in the effectiveness of PEG-IFN treatment between
fixed and weight adjusted doses, between standard and low
doses of ribavirin and, finally, between patients with different
degrees of baseline fibrosis (between cirrhotic and non-cir-
rhotic patients)?
Therapy of chronic hepatitis C may be improved either by
selecting patients with a high likelihood of response or by
identifying the optimal treatment regimen of PEG-IFN and
ribavirin. Accurate prediction of pretreatment responsiveness
to antiviral therapy in the individual patient, however,
remains an elusive goal, as the accuracy and reliability of the
actual prediction rules are questionable. Many RCTs have
been conducted to identify the ideal dose of PEG-IFN, as well
as of ribavirin, which would increase the cost-effectiveness of
therapy in the individual patient [12-19]. However, the optimal
treatment schedule remains ill-defined, as the results of the
published studies are inconclusive or conflicting.
An important issue not entirely solved by these studies is
whether increased body weight adversely effects response to
treatment and whether weight-based dosing should be used
even among those who are overweight. It is widely known
that chronic hepatitis C runs a more severe course in the obese
patient [20-22] and that responsiveness to standard IFN, either
alone or in combination with ribavirin [23], is markedly
diminished by an high body mass index (BMI). One disputed
point in hepatitis C therapy is whether PEG-IFN should be
dosed according to body weight or given as a fixed dose.
When weight-based dosing is used, it is unclear whether there
should be upper and lower limits to the amounts of drug
administered. Dose modifications are often required during
combination therapy. Most evidence suggests that decreasing
the dose of PEG and/or ribavirin does not have a major influ-
ence on response rate [7].
A recently published Italian RCT, involving genotype 1
treatment-naive patients, compared the efficacy and safety of
an induction dose of PEG-IFN-α2b 100 µg/week for 8 weeks
followed by a fixed dose of 50 µg/week for the next 48 weeks,
with IFN-α2b 6 MU on alternate days for 48 weeks; both regi-
mens given in combination with a standard dose of ribavirin
(1000 – 1200 mg/day) [19]. The study, using a fixed dose of
PEG-IFN-α2b, showed in a post hoc analysis that there was no
significant correlation between the SVR rate and the doses of
PEG-IFN-α2b received based on body weight. Interestingly,
the SVR rates achieved in a previous study by Manns et al. [16],
which used a higher dose of PEG-IFN (1.5 µg/kg), paralleled
the rates achieved by the Italian RCT in which patients
received, on average, PEG-IFN 0.85 µg/kg. This suggests that
Risk difference 95% CI
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Total 445 z = 5.54; 2p < 0.00001
Figure 1. Meta-analysis of 12 controlled trials of standard IFN treatment for acute hepatitis C using a random effects model
with sustained virological response as the end point. Risk difference and 95% CI for each study and the pooled estimate of the
treatment effect with its confidence interval are plotted. Studies are arranged chronologically (reproduced with permission from Licata A,
Di Bona D, Schepis F, Shaied L, Craxì A, Cammà C: J. Hepatol. (2003) 39:1056-1062).
MU: Megaunits; N: Number of patients.
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the investigators in this earlier study used higher doses of PEG-
IFN than is actually necessary. Indeed, we believe that the rec-
ommended dose of PEG-IFN-α2b should be redefined by fur-
ther trials, as the results from one other monotherapy study [14]
indicate that 1.0 µg/kg/week was the most beneficial dose.
Finally, the fact that many patients who were treated with
PEG-IFN [12-19] needed a reduction of the dose, yet did not
show a reduced SVR, suggests that the currently recommended
doses may be unnecessarily high, especially for patients with
genotypes 2 and 3.
Weight-based ribavirin dosing is even more difficult to
assess. Ribavirin is a drug with a narrow divide between effec-
tiveness and toxicity [24], and works through accumulation in
the body. The practice of administering ribavirin
1000 mg/day for patients < 75 kg in weight, and at
1200 mg/day for those above, evolved as a consequence of
experience gained in studies of persons with HIV. The pivotal
trials of the combination with standard IFN [25,26] adopted
this scheme. Recently published RCTs [16-19] have attempted
to identify the ideal dose of ribavirin with the aim of maximis-
ing the cost-effectiveness of treatment, particularly in persons
infected with genotype 1b. The effectiveness of the standard
dose of ribavirin (1000 – 1200 mg/day) used in patients with
genotype 1 in the Italian RCT [19] is similar to that of the
results of two previously reported trials [17,18], in which
PEG-IFN-α2a was administered in combination with a stand-
ard dose of ribavirin for 48 weeks. These data all provide evi-
dence that a full standard dose of ribavirin, administered over
a long course, is particularly needed for genotype 1-infected
patients. The observation of Manns et al. [16], who reported in
a post hoc analysis that a dose–response relationship exists
between the dose of ribavirin selected on the basis of body
weight and the rate of SVR achieved in t e low dose
(800 mg/day) ribavirin arm of the trial, was not confirmed.
This study identified ribavirin > 10.6 mg/kg as the lower end
of the optimum dose range. However, the mean body weight
dose of ribavirin administered in the low-dose ribavirin arm of
the study was 9.7 mg/kg. This suboptimal dose of ribavirin
could explain the disappointing rate of SVR observed (30%)
in patients with genotype 1 and high viral load in comparison
to standard IFN (29%).
Whatever the dose administered, PEG-IFN and ribavirin
combination therapy is generally poorly tolerated by patients
[12-19]. In the Italian RCT [19], the investigators found that
adverse events were the main cause for discontinuation occur-
ring during the first 12 – 24 weeks of treatment, as previously
reported [16]. Not surprisingly, changes in fatigue and SF-36
mental and physical summary scores between baseline and
24 weeks of treatment significantly predicted treatment dis-
continuation [27]. The Italian RCT failed to identify any dif-
ference in the baseline characteristics between compliers and
non compliers; furthermore, nor did these authors find any
relationship between weight-based dosing of both treatments
and treatment adherence [19]. Future trials comparing differ-
ent regimens using quality assurance measures to document
adherence to treatment and the safety profile are still needed.
However, even with accurate compliance data, tolerability
remains difficult to evaluate because compliance is a non-ran-
domised process within the trial, which interacts with prog-
nostic factors and treatment response [28,29].
Finally, it must be remembered that the optimal regimen in
the typical patient with chronic hepatitis C may not be opti-
mal for subgroups of patients (such as those with cirrhosis) or
patients with comorbidities (such as HIV infection or renal
disease). In the Italian RCT [19], age and degree of fibrosis at
biopsy, but not body weight, strongly predicted a SVR to
combination therapy with PEG-IFN. These findings are in
keeping with other studies, emphasising the importance of
age and liver fibrosis in IFN unresponsiveness, and suggest
that antiviral treatment should be offered to all eligible
patients with genotype 1 as early as possible in the course of
their liver disease. Patients with chronic hepatitis C who have
contraindications to the use of ribavirin should receive PEG
monotherapy and be treated for 48 weeks.
4.   What is the histological benefit of antiviral 
therapy?
Patients with chronic hepatitis C typically undergo liver
biopsy to determine the severity of disease and thereby assess
the urgency of treatment [30]. The histological findings on
biopsy also enable the clinician to evaluate the probability of a
response to antiviral therapy. As a tool to evaluate treatment
response, however, histology has several significant limitations
and sources of bias: 
• The histological picture of chronic hepatitis C is mild-to-
moderate in most cases; therefore, the relatively small
change induced by IFN can be difficult to assess with accu-
racy and reliability.
• Many factors might influence the interpretation of the his-
tological findings: inconsistency in the definition of patho-
logical features, technical processing of the specimens,
sampling variation.
• In most trials, a preliminary assessment of the intra/inter-
observer variations in the course of semiquantitative evalua-
tion of histological lesions is not reported. This can be a
particularly important source of bias in cooperative studies,
or in studies where the biopsy specimens were observed by
different pathologists.
• The HAI by the Knodell’s method and its modifications are
measured on an ordinal scale with non-constant intervals,
possibly leading to bias in the cumulative or comparative
assessment of data.
• The biopsy specimens reflect a single time-point in a long-
term dynamic process and that develops at varying rates
and with differing responses to treatment. Accordingly,
truly accurate histological assessment of the chronic process
requires repeated liver biopsy that obviously cannot accom-
plished because of the invasive nature of the procedure.
 
 
 
 
 
 
 
Au
tho
r P
roo
f 
Cammà, Licata, Cabibbo, Latteri & Craxì
Expert Opin. Pharmacother. (2005) 6(3) 5
In 1997, a conventional meta-analysis [31] based on summary
data of 17 randomised controlled trials (n = 1223) showed
that standard IFN significantly improved liver histology com-
pared with no treatment. Histological improvement was
clearly related to antiviral responses. However, drawing firm
conclusions based on the results of this conventional meta-
analysis is hampered by the considerable heterogeneity in the
trials included and by the lack of individual patient data. So
far, several large multi-centre RCTs have clearly demonstrated
that PEG-IFN produces a significantly greater SVR when
compared with standard IFN. Nonetheless, the results of pub-
lished studies on the effect of these new drugs on liver histol-
ogy remain inconsistent, and the overall assessment of the
treatment effect is difficult to evaluate. To overcome some of
the limitations mentioned above and, to improve estimates of
effect of size, the results of a recently-published meta-analysis
[32] of individual patient data (MIPD) will be summarised.
The primary goals of this MIPD were to determine the dif-
ferences between PEG-IFN-α2a and IFN-α2a with respect to
changes in liver histology, and to identify predictors (clinical,
biochemical and virological) of histological improvement.
In this study of 1013 patients who had paired liver biop-
sies taken before and 24 weeks after the end of the treat-
ment, we showed that interferon treatment improves liver
histology and that this effect is more marked with PEG-
IFN-α2a than with standard IFN [32]. More specifically, this
MIPD has conclusively shown that an impressive reduction
in necroinflammatory activity (Table 1), as well as in fibrosis
(Table 2), is achieved post-treatment only in virological sus-
tained responders and, to a lesser degree, in relapsers;
whereas negligible changes in necroinflammation and no
significant changes in fibrosis after treatment occurred in
nonresponders. Moreover, these data indicate that patients
with a low BMI and a high alanine aminotransferase level at
baseline have the highest likelihood of histological improve-
ment. Although the mechanisms responsible for the effect of
BMI on liver histology are unknown, a practical recommen-
dation may be to lower body weight in overweight or obese
patients before starting therapy. This statement is strength-
ened by the observation that we found an improvement of
fibrosis in the small proportion of nonresponders with the
lowest BMI.
Study
After treatment Before treatment SMD Weight SMD
n mean (sd) n mean (sd) (95% CI random) (%) (95% CI random)
01 Non-responders
Heathcote 180
Heathcote 90
Pockros 135
Pockros 180
Zeuzem 180
Subtotal (95% CI)
Heterogeneity
34
33
70
61
35
233
Chi-square 2.97 (df = 4); p = 0.56
8.91 (2.10)
8.72 (2.18)
7.54 (2.46)
6.93 (2.63)
6.51 (2.42)
34
33
70
61
35
233
9.41 (1.72)
8.42 (2.13)
7.25 (2.37)
7.42 (2.26)
6.57 (2.67)
02 Relapsers
Heathcote 180
Heathcote 90
Pockros 135
Pockros 180
Zeuzem 180
Subtotal (95% CI)
Heterogeneity
10
18
48
54
66
196
Chi-square 5.73 (df = 4); p = 0.22
8.60 (2.50)
7.88 (2.86)
6.91 (2.26)
6.29 (2.32)
6.16 (2.36)
10
18
48
54
66
196
9.70 (1.49)
9.16 (1.94)
6.79 (2.52)
7.42 (2.27)
7.45 (2.44)
03 Sustained responders
Heathcote 180
Heathcote 90
Pockros 135
Pockros 180
Zeuzem 180
Subtotal (95% CI)
Heterogeneity
25
10
51
48
81
215
Chi-square 4.57 (df = 4); p = 0.33
5.04 (2.17)
5.90 (1.96)
4.24 (2.04)
3.97 (1.98)
3.57 (1.63)
25
10
51
48
81
215
9.66 (1.63)
9.80 (1.54)
7.64 (2.48)
8.02 (2.49)
7.31 (2.50)
-4 -2 0 2 4
14.5
14.1
30.1
26.2
15.1
100z = 0.40;
p = 0.7
Treatment effect
-0.26 (-0.73, 0.22)
0.14 (-0.35, 0.62)
0.12 (-0.21, 0.45)
-0.20 (-0.49, 0.45)
-0.02 (-0.49, 0.45)
-0.04 (-0.22, 0.14)
z = 2.89;
p = 0.004
Treatment effect
5.1
9.2
25.0
27.4
33.3
100
-0.51(-1.41, 0.38)
-0.51 (-1.18, 0.15)
0.05 (-0.35, 0.45)
-0.49 (-0.87, -0.11)
-0.53 (-0.88, -0.19)
-0.37 (-0.62, -0.12)
9.4
4.0
26.5
21.9
38.2
100
z = 14.17;
p = < 0.00001
Treatment effect
-2.37 (-3.11, -1.63)
-2.12 (-3.26, -0.98)
-1.49 (-1.92, -1.05)
-1.79 (-2.26, -1.31)
-1.76 (-2.12, -1.40)
-1.77 (-2.02, -1.53)
After treatment Before treatment
Table 1. Meta-analysis (using a random-effects m del) of three RCTs comparing histological score before and after treatment
in patients with chronic hepatitis C treated with PEG-IFN-α2a. The standardised mean difference (SMD) and 95% CI for activity,
according to virological response to PEG-IFN-α2a, for nonresponders, relapsers and sustained responders are shown. Reproduced with
permission from Camma C, Di Bona D, Schepis F et al.: Hepatology (2004) 39:333-342.
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It has been suggested that IFN combined with ribavirin
slows down the natural progression of fibrosis in virological
nonresponders in addition to responders and relapsers [33,34].
This discrepancy with the findings of the MIPD is probably
due to the fact that the authors based their analysis on the
comparison between the ‘fibrosis progression rate per year’
before and after treatment [33,34]. There are flaws in using the
fibrosis progression rate as a basis for modelling the indication
for treatment due to the inaccurate estimations of the dura-
tion of infection and the nonlinearity of progression of fibro-
sis over time. Finally, a complete reversal of fibrosis after
treatment was not seen in any of the 198 (19.6%) patients
with cirrhosis studied. More specifically, the MIPD provides
evidence that the fibrosis score decreases in only 33% of
patients with cirrhosis after treatment, and in none of the
patients did cirrhosis actually disappear.
There is sufficient information to reach the following con-
clusions: PEG-IFN-α is more effective than conventional IFN
in improving liver histology; monotherapy with PEG-IFN
induces a marked reduction in staging in virological sustained
responders and to a lesser degree in relapsers after
24 – 48 weeks of treatment but provides no benefit to nonre-
sponders. Therefore, the use of maintenance therapy in viro-
logical nonresponders with the aim of improving histology
should be considered experimental and of unproven benefit.
5.  What is the overall effect of IFN treatment 
on the prevention of hepatocellular carcinoma 
in hepatitis C virus-related cirrhosis?
The extensive application of surveillance programmes for
early detection of small HCC has increased the opportunity
to detect tumours at a subclinical stage when these lesions are
potentially responsive to curative treatments [35]. Nonetheless,
the 5-year survival rate of patients with small (< 5 cm) HCC
undergoing surgical or percutaneous ablation is < 50% [36,37].
This holds true even within intensive screening programmes
because of the almost constant presence of underlying cirrho-
sis and of the high risk of local and distant recurrence, even
though treatment had been considered radical. The benefits
of orthotopic liver transplantation (OLT) in patients with
small HCC are limited by the high rate of tumour progression
Study
After treatment Before treatment SMD Weight SMD
n mean (sd) n mean (sd) (95% CI random) (%) (95% CI random)
01 Non-responders
Heathcote 180
Heathcote 90
Pockros 135
Pockros 180
Zeuzem 180
Subtotal (95% CI)
Heterogeneity
02 Relapsers
Heathcote 180
Heathcote 90
Pockros 135
Pockros 180
Zeuzem 180
Subtotal (95% CI)
Heterogeneity
03 Sustained responders
Heathcote 180
Heathcote 90
Pockros 135
Pockros 180
Zeuzem 180
Subtotal (95% CI)
Heterogeneity
After treatment Before treatment
34
33
70
61
35
233
Chi-square 2.94 (df = 4); p = 0.57
3.73 (0.62)
3.48 (0.90)
1.78 (1.24)
1.70 (1.08)
1.43 (0.98)
34
33
70
61
35
233
3.82 (0.39)
3.75 (0.43)
1.86 (1.30)
1.97 (1.21)
1.28 (0.92)
10
18
48
54
66
196
Chi-square 3.20 (df = 4); p = 0.53
3.20 (0.92)
3.17 (1.25)
1.44 (0.94)
1.50 (1.02)
1.20 (0.82)
10
18
48
54
66
196
3.80 (1.42)
3.67 (0.48)
1.94 (1.10)
1.61 (1.02)
1.51 (1.03)
25
10
51
48
81
215
Chi-square 8.31 (df = 4); p = 0.08
2.64 (1.32)
3.20 (1.23)
1.24 (0.78)
1.10 (0.72)
1.00 (0.86)
25
10
51
48
81
215
3.86 (0.37)
3.85 (0.42)
1.45 (0.87)
1.75 (1.09)
1.40 (0.96)
-0.5-1.0 0.5 1.0
z = 1.45;
p = 0.15
Treatment effect
z = 3.38;
p = 0.0007
Treatment effect
z = 3.89;
p < 0.00010
Treatment effect
9.4
14.6
14.0
30.2
26.1
15.1
100
-0.17 (-0.65, 0.30)
-0.38 (-0.87, 0.11)
-0.06 (-0.39, 0.27)
-0.23 (-0.59, 0.12)
0.16 (-0.31, 0.63)
-0.13 (-0.32, 0.05)
4.8
9.1
24.2
28.1
33.8
100
-0.80 (-1.72, 0.12)
-0.52 (-1.18, 0.15)
-0.48 (-0.89, -0.08)
-0.11 (-0.48, 0.27)
-0.33(-0.67, 0.01)
-0.34 (-0.54, -0.14)
10.0
4.5
25.2
21.6
38.7
100
-1.24 (-1.85, -0.63)
-0.68 (-1.58, 0.23)
-0.25 (-0.63, 0.13)
-0.70 (-1.11, -0.29)
-0.44 (-0.74, -0.13)
-0.59 (-0.89, -0.30)
Table 2. Meta-analysis (using a random-effects model) of three RCTs comparing histological score before and after treatment
in patients with chronic hepatitis C treated with PEG-IFN-α2a. The standardised mean difference (SMD) and 95% CI for fibrosis,
according to virological response to PEG-IFN-α2a, for nonresponders, relapsers and sustained responders are shown. Reproduced with
permission from Camma C, Di Bona D, Schepis F et al.: Hepatology (2004) 39:333-342.
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and death due to liver disease while still on the waiting list.
This applies even to countries with a high number of organs
available for OLT [38].
Although early diagnosis and effective treatments are para-
mount in controlling the death rate of patients with HCC,
the importance of cancer chemoprevention has gradually
emerged because advanced (i.e., large or locally invasive)
HCC is difficult to cure. As the basic mechanism of all can-
cer development results from accumulation of epigenetic and
genetic alterations in cells, the current concept of multistage
carcinogenesis has promoted chemoprevention to the stage
of a new medical science [39]. Therefore, HCC (chemo)pre-
vention remains a major issue in the long-term management
of cirrhotic patients, especially where HCV and overt or
occult hepatitis B virus (HBV) infection are the leading
cause of chronic liver disease (≤ 80% in the Mediterranean
area) [40].
Chemoprevention may be defined as the use of natural or
synthetic agents to reverse, suppress or prevent premalignant
lesions from progressing to invasive cancer [41]. A chemo-
prevention programme for HCC should fulfill the following
prerequisites: identification of the risk factors for HCC;
determination of the pathogenetic mechanisms of liver car-
cinogenesis, as well as of the genetic markers that identify the
early events in the carcinogenetic process and the possible
availability of animal tumour models; and evaluation of the
available data from epidemiological and clinical studies on
candidate chemopreventive agents.
Chemoprevention of HCC may be classified into three cat-
egories: 
• Primary: preventing cancer in healthy subjects who are at
high risk of exposure to aetiologic factors known to cause
chronic liver disease.
• Secondary: preventing cancer in those with premalignant
conditions (e.g., HCC prevention in patients with cirrhosis).
• Tertiary: preventing recurrence in patients cured of an ini-
tial cancer.
Pooling the available evidence in the setting of secondary
chemoprevention and assessing it by meta-analysis, these
authors have previously critically reviewed the literature
regarding the role and effectiveness of IFN in preventing
HCC in patients with HCV-related cirrhosis [42].
It has been argued that long-term suppression of viral repli-
cation could reduce hepatocyte turnover and lessen the risk of
dysplasia and cancer. In 1995, a small RCT showed that the
incidence of HCC in patients with HCV cirrhosis was
decreased when compared with untreated controls [43]. In the
wake of this study, several controlled trials were performed,
mostly in patients with HCV infection. These studies which
mostly assessed collected cohorts retrospectively and were of a
relatively small size, showed a marked degree of heterogeneity,
-0.5 -0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4 0.5
Risk difference 95% CI
Study Year N
1. Mazzella
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Figure 2. Meta-analysis of the 20 controlled trials of IFN for prevention of hepatocellular carcinoma in patients with
hepatitis C virus-related cirrhosis. Risk difference and 95% CI for each study and the pooled estimate of the treatment effect with its
confidence interval are plotted on the graph. 
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thus making it difficult to assess the actual level of benefit
obtained by IFN treatment.
Thus, a number of important questions still remain unan-
swered by the available studies: is the risk of HCC in HCV-
related cirrhosis reduced by IFN therapy? If a risk reduction
truly exists, does the benefit apply to all patients with HCV-
related cirrhosis? Is a sustained response to IFN required to
reduce the HCC incidence?
We updated the information gathered in the previous sys-
tematic review of the literature [42] in order to evaluate
whether newly acquired information supports and even
extends the view that IFN reduces the incidence of HCC in
patients with viral cirrhosis. The effect of IFN on cancer inci-
dence (three RCTs and 17 nonrandomised controlled trials
[NRCTs]: 4659 patients) is shown in Figure 2. These studies
indicate that in all but one of the 20 evaluable treatment tri-
als, IFN appeared to decrease the HCC rate, with a significant
difference being observed in 13. The pooled estimate of the
treatment effect was significantly in favour of a preventive
effectiveness of IFN (RD: -12.2; 95% CI = -8.4 to -16.1; p <
0.00001).
We found remarkable heterogeneity among the studies (chi-
square for heterogeneity 69.1 with 19 d.f.; p < 0.0001), the
most prominent being the difference in magnitude of the treat-
ment effect on the risk of cancer (‘quantitative heterogeneity’).
Large differences were observed in the baseline risk of HCC
among the different trials: the HCC rate in the untreated
group ranged from 6.8 to 73%. These two trials represent the
extremes of the range of effectiveness: Sofia [44] found no effect
of IFN on prevention of HCC, whereas the highest preventa-
tive benefit of treatment was observed by Nishiguchi et al. [43].
The small sample size of the latter study could be the result of
unbalanced randomisation. This is suggested by t e low cancer
rate in the treated group (26%) compared with the extremely
high cancer rate in the control group (73%). The RD of each
trial ranged from -33.3 to +3.9%. A pooled analysis excluding
both outliers reporting the highest [43] and lowest [44] benefit of
IFN treatment once again yielded inconsistent results. We
searched for the sources of this variability and found a signifi-
cant relation between the IFN benefit and HCC rate among
untreated patients using both parametric and nonparametric
tests (Pearson coefficient: r = -0.77; p = 0.0001; Spearman rank
correlation coefficient: r = -0.74; p = 0.0001).
As the 20 studies show a marked heterogeneity, subgroup
analyses were carried out in relation to the different design
(RCTs versus NRCTs), ethnic origin of patients (European
versus Oriental studies), the HCC incidence in the untreated
group (rate in controls ≥ 20% versus < 20%) and the type of
publication (full papers versus abstracts). Consistent results
were only observed when assessing data pooled from RCTs,
European reports, studies published as full papers and from
trials in which HCC frequency among untreated patients was
< 20% during the follow-up period, ranging between 32 and
76 months.
To test whether the difference in the HCC incidence
between treated and untreated groups persisted after adjust-
ment for potentially relevant confounding factors, we per-
formed a logistic regression model including IFN treatment,
length of follow-up, cancer rate among untreated patients,
design of study (RCTs versus NRCTs), type of publication
and ethnic origin of patients. The final model shows that cir-
rhotic patients treated with IFN have a lower likelihood of
developing HCC (OR: 0.28), after adjusting for covariates.
Separate subanalyses were performed to evaluate any possible
evidence of differential benefit on HCC prevention according
to biochemical response to IFN. Analysis by response to treat-
ment showed the pooled RD was -19.1% (95% CI -13.1 to
-25.2; p < 0.00001) among sustained biochemical responders,
without a significant heterogeneity (chi-square for heteroge-
neity 15.35; p = 0.053). The NNT, in studies that included
only those with consistent results, was 10. When only patients
from these studies who had a sustained response were evalu-
ated, the NNT dropped to 5.2.
The results of this meta-analysis demonstrate that the het-
erogeneity in the magnitude of the preventive effect of IFN
on the risk of cancer is the most impressive feature of these
studies. This inconsistency among trials is not surprising
because of potential biases in patient selection and in alloca-
tion of patients to treatment groups. It is also evident that
studies with high HCC rates among controls are more likely
to demonstrate a higher estimate of treatment efficacy,
whereas those with low rates are more likely to show no ben-
efit.
Regarding HCV cirrhosis, the pooled data suggested a
slight preventive effect of IFN on HCC development in
patients with HCV cirrhosis. The magnitude of this effect was
low, and the observed benefit might be due to spurious associ-
ations. The preventative effect was more evident among sus-
tained biochemical responders to IFN, which intrinsically
represent a small proportion of all cirrhotic patients.
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